Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Bild på Shai Mulinari. Privat bild.

Shai Mulinari

Docent | Universitetslektor

Bild på Shai Mulinari. Privat bild.

Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries

Författare

  • Shai Mulinari
  • Luc Martinon
  • Pierre-Alain Jachiet
  • Piotr Ozieranski

Summary, in English

The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the need for transparency laws similar to the US Physician Payment Sunshine Act. We conducted a comparative analysis of 20 large companies’ payment disclosures in seven European countries in 2017–2019. The data was extracted as part of eurosfordocs.eu, a novel transparency project that scrapes and integrates publicly available databases and disclosures. Our analysis of EUR 735 million showed marked differences in country payment patterns. For example, payment totals per registered doctor were substantially larger in Spain and lowest in Sweden. There were significant country and company differences in individualized data completeness. Only 19% of totals were reported with recipient names in Germany, compared to Ireland (59%), the United Kingdom (60%), Italy (67%), Switzerland (73%), Sweden (79%) and Spain (100%), with little or no improvement over time. Payment data in Spain was particularly difficult to extract. Thus, in no country did self-regulation generate comprehensive individualized data allowing for building an accurate picture of financial relationships between the industry and healthcare professionals. We conclude that the cultures and policies of countries and companies create structural problems of data inaccessibility and incompleteness within the self-regulatory framework. Therefore, this study supports calls for a Europe-wide “Sunshine Act” to achieve real transparency of drug company payments.

Avdelning/ar

  • Sociologi

Publiceringsår

2021-07-01

Språk

Engelska

Sidor

915-922

Publikation/Tidskrift/Serie

Health Policy

Volym

125

Issue

7

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Sociology (excluding Social Work, Social Psychology and Social Anthropology)
  • Health Care Service and Management, Health Policy and Services and Health Economy

Status

Published

Projekt

  • What can be learnt from the new pharmaceutical industry payment disclosures? A network and policy analysis of ties between companies and health professionals and organisations
  • Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations

ISBN/ISSN/Övrigt

  • ISSN: 1872-6054